PROM1 and glioblastoma: Meanwhile, the phase I clinical trial of the DC vaccine targeting GBM stem-like cells (GSC) in both newly diagnosed and recurrent GBM patients76 reported encouraging results for stem-like cell targeting strategy, consistent with results of a previous DC vaccine phase II study targeting GSC marker, CD133.77